AIP
AXSM icon

Ameritas Investment Partners’s Axsome Therapeutics AXSM Stock Holding History

Ameritas Investment Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,381
Closed -$571K – 3188
2026
Q1 		$571K Hold
3,381
– – 0.02% 798
2025
Q4 		$618K Hold
3,381
– – 0.02% 765
2025
Q3 		$411K Sell
3,381
-751
-18% -$84.6K 0.01% 894
2025
Q2 		$431K Buy
4,132
+383
+10% +$40.6K 0.01% 897
2025
Q1 		$437K Sell
3,749
-103
-3% -$11.7K 0.02% 878
2024
Q4 		$326K Buy
3,852
+162
+4% +$14.9K 0.01% 1036
2024
Q3 		$332K Hold
3,690
– – 0.01% 1032
2024
Q2 		$297K Hold
3,690
– – 0.01% 1023
2024
Q1 		$294K Hold
3,690
– – 0.01% 1043
2023
Q4 		$294K Buy
3,690
+163
+5% +$10.9K 0.01% 1039
2023
Q3 		$247K Buy
3,527
+810
+30% +$60.5K 0.01% 1054
2023
Q2 		$195K Buy
2,717
+153
+6% +$11.3K 0.01% 1144
2023
Q1 		$158K Hold
2,564
– – 0.01% 1239
2022
Q4 		$179K Buy
2,564
+232
+10% +$13.9K 0.01% 1213
2022
Q3 		$104K Buy
2,332
+153
+7% +$7.64K ﹤0.01% 1459
2022
Q2 		$83K Hold
2,179
– – ﹤0.01% 1643
2022
Q1 		$90K Hold
2,179
– – ﹤0.01% 1720
2021
Q4 		$82K Hold
2,179
– – ﹤0.01% 1795
2021
Q3 		$72K Hold
2,179
– – ﹤0.01% 1902
2021
Q2 		$147K Sell
2,179
-175
-7% -$10.5K 0.01% 1475
2021
Q1 		$133K Hold
2,354
– – 0.01% 1486
2020
Q4 		$192K Hold
2,354
– – 0.01% 1183
2020
Q3 		$168K Hold
2,354
– – 0.01% 1122
2020
Q2 		$194K Buy
2,354
+105
+5% +$8.08K 0.01% 1038
2020
Q1 		$132K Buy
2,249
+100
+5% +$8.15K 0.01% 1116
2019
Q4 		$222K Hold
2,149
– – 0.01% 1030
2019
Q3 		$43K Hold
2,149
– – ﹤0.01% 1968
2019
Q2 		$55K Buy
+2,149
New +$43.1K ﹤0.01% 1860
2017
Q2 		– Sell
-866
Closed -$3K – 2999
2017
Q1 		$3K Buy
+866
New +$4.14K ﹤0.01% 2893

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Ameritas Investment Partners's AXSM Position: Q2 2026 in Review

Ameritas Investment Partners sold out of Axsome Therapeutics (AXSM) in Q2 2026, closing a stake of 3,381 shares — an estimated $571K sold.

Ameritas Investment Partners first reported a position in AXSM in Q1 2017 and held it in 29 quarters. The position peaked at $618K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Ameritas Investment Partners reported no remaining Axsome Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ameritas Investment Partners sold 3,381 Axsome Therapeutics shares in Q2 2026, an estimated $571K.
  • Ameritas Investment Partners first reported a position in Axsome Therapeutics in Q1 2017 and held it in 29 quarters.
  • Ameritas Investment Partners's Axsome Therapeutics position peaked at $618K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.